See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Flutamide-induced hepatotoxicity: A case report

Accepted: May 12, 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Flutamide is a non-steroidal anti-androgen drug effective in the management of prostatic carcinoma. The drug appears to be well tolerated with mild gastrointestinal adverse events and gynecomastia. Flutamide-induced hepatotoxicity may range from minor elevation in liver enzymes to hepatic failure. Here, we tried to discuss the possibility of hepatotoxicity induced by flutamide as antiandrogen therapy in a patient with prostatic adenocarcinoma. Here we present a 75-year-old man who commenced flutamide as a postoperative anti-androgen for prostatic adenocarcinoma for two months. He had markedly elevated levels of liver enzymes due to acute liver failure and subsequent multi-organ failure. The patient died after the failure of the resuscitation measures. The temporal relationship between the flutamide initiation and the emergence of hepatotoxicity is not clear, with a possible latency of 12-16 weeks. Careful monitoring of liver function test during flutamide therapy is essential to prevent serious hepatotoxicity.
Downloads
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.